What is the estimated business value of DEPHARM?

An indicative valuation band is available for DEPHARM. The exact public range is visible with a free account; a precise, defensible valuation requires normalised owner or advisor data.

When was DEPHARM founded?

DEPHARM was founded in 1991 and is registered with Belgian Crossroads Bank for Enterprises (KBO), incorporated as a Besloten Vennootschap.

What sector does DEPHARM operate in?

DEPHARM is registered under NACE 46460: NACE 46460. That places the business within the Belgian cluster for this activity.

Where is DEPHARM based?

According to the company registry, DEPHARM is based in Wavre, BE.

When did DEPHARM last file annual accounts?

The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via Belgian Crossroads Bank for Enterprises (KBO).

BE · 0445912760

DEPHARM

NACE 46460 in Wavre · BE. Public registry data, filed financials, business card, and annual valuation trend on one indexed company profile.

Wavre · BEFiled 2025Updated Jul 17, 2026

DEPHARM

NACE 46460

1991Wavre, BE

Your value, under scrutiny

What could a buyer discount here?

This is a first signal from public filings, not a sale price. It surfaces where a business may be exposed before a lender, buyer or successor turns uncertainty into a discount. Add current figures privately to see what to strengthen first.

Context: Stable SMEMethod: Public accounts multiple

Latest estimate

First value signal

The worst time to discover a weak spot is when someone else prices it.

A lower price rarely starts at the negotiation table. It starts with risks left unaddressed. Sign in to see what may weaken this business before financing, succession or a sale makes the question urgent.

See what could be weakening this business

Free · private by default

Value pathSame pace: market decides.

Growth goalsPublic preview

Revenue growth+0%/yr

EBITDA growth+0%/yr

EBITDA margin+0 pp

This is a starting point, not a sale price. Owner context reveals the risks that can become a discount—and the moves that make the business stronger.

Public figures

Fiscal year	Revenue	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€1,244,074	€404,399	€26,751,203	€25,301,814	-
202431 Dec 2024	€1,165,809	€67,411	€26,352,610	€25,178,909	-

DEPHARM

DEPHARM

What could a buyer discount here?

The worst time to discover a weak spot is when someone else prices it.

Registered details

How this valuation is built

About DEPHARM

Filed annual accounts by fiscal year

Frequently asked questions about DEPHARM

100% SISTERS

12 FLY2

130R

15SQUARE

What could a buyer discount here?

The worst time to discover a weak spot is when someone else prices it.

Registered details

How this valuation is built

About DEPHARM

Filed annual accounts by fiscal year

Frequently asked questions about DEPHARM

Other companies like this

100% SISTERS

12 FLY2

130R

15SQUARE